DORAL, FL--(NewMediaWire - Dec 21, 2015) - In Ovations Holdings, Inc. (OTC PINK: INOH) has announced an agreement with Al Lee & Associates to promote and market a new comprehensive service that has been developed and tested with guidance from regulating authorities to greatly simplify the Annual Wellness Visit (AWV) that is called for in the Affordable Care Act (ACA). Based on the general guideline that the average doctor or clinic serving Medicare patients has approximately 1,000 Medicare patients, and the average reimbursement for the three billing codes charged for a basic AWV is $210 with up to $500 in ancillary billings, INOH projects that it will enroll about 30 clients in 2016 and will generate $6-15 Million in new revenue for its client medical providers.

The AWV is a heath screen designed to anticipate chronic medical problems in patients before they become serious. For most diseases, early detection and treatment can greatly reduce both the cost and suffering a patient must bear. Chronic ailments account for a major portion of our national healthcare costs.

INOH management has made a strategic decision to consolidate its focus on this new Medicare medical division, which it feels represents the most value and growth for the company and its shareholders. We are excited to be able to announce shortly some of these diagnostic screening products that are currently approved and helping patients. INOH is also planning to introduce the concept of AWV-only clinics. These chains of clinics will offer AWVs and ancillary preventative services to patients. The workflow of the health screenings is different from most practices' usual pattern, and if a practice determines that it would be more efficient to refer out its Medicare patients for the screenings, such specialized clinics will be the perfect resource.

In Ovations Holdings, Inc.

"Safe Harbor Statement" Under The Private Securities Litigation Reform Act of 1995: The statements in this presentation that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. Additional risks and uncertainties are set forth in the Company's Annual Report for the year ended June 30, 2013, and the Company's Quarterly Report for the first quarter ended September 30, 2013. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.